Chemical formula: C₁₃H₁₇N Molecular mass: 187.286 g/mol PubChem compound: 26757
Selegiline is indicated for:
Population group: only adults (18 years old or older)
Selegiline is indicated for the treatment of Parkinson’s disease, or symptomatic parkinsonism. It is used as an adjunct to levodopa (with or without decarboxylase inhibitor). Selegiline in combination with maximal levodopa therapy is indicated particularly in patients who experience fluctuations in their condition such as ‘end-dose’ type fluctuations, ‘on-off’ symptoms or other dyskinesias.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Selegiline is indicated for the treatment of Parkinson’s disease, or symptomatic parkinsonism. It may be used alone in early Parkinson’s disease for symptomatic relief to delay the need for levodopa (with or without decarboxylase inhibitor).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Selegiline is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
